However, C6orf120 expression was demonstrated to be significantly increased in tumor biopsies from patients who had a poor response to neoadjuvant CRT, when compared to good responders (Figure 6B), suggesting that the decreased expression of miR-17-5p in poor responder tumors may provide a mechanism for increased C6orf120 expression in vivo. The gene discussed is C6orf120; the disease is neoplasm.